Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.35 |
| ▸ | FAAH | O00519 | 12/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6525256 | 0.85 | OGA (0.36) | OGACYP3A4CYP2D6FAAHGABRA1 | |
| SCHEMBL6516955 | 0.82 | CYP3A4 (0.33) | OGACYP3A4CYP2D6FAAHGABRA1 | |
| SCHEMBL1036577 | 0.82 | CYP3A4 (0.47) | OGACYP3A4CYP2D6FAAHGABRA1 | |
| SCHEMBL6521424 | 0.79 | GPR55 (0.37) | OGACYP3A4CYP2D6CNR1CNR2 | |
| SCHEMBL6518914 | 0.78 | OGA (0.36) | OGACYP3A4CYP2D6 | |
| SCHEMBL6521897 | 0.77 | F10 (0.37) | OGA | |
| SCHEMBL1037447 | 0.76 | CYP3A4 (0.46) | OGACYP3A4CYP2D6FAAHGABRA1 | |
| SCHEMBL6516046 | 0.75 | HPGD (0.37) | OGA | |
| SCHEMBL6515954 | 0.75 | ACACB (0.34) | OGACYP3A4CYP2D6FAAH | |
| SCHEMBL6522876 | 0.75 | HPGD (0.40) | OGAHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053982-A1 | ETHER BENZYLIDENE PIPERIDINE 5-MEMBERED ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS | PFIZER INC. (US) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053982-A1 | ETHER BENZYLIDENE PIPERIDINE 5-MEMBERED ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS | FAAH, FAAH2, CNR2 | OGA 1857/4885CYP3A4 524/4885CYP2D6 316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.